 BioXcel Therapeutics Inc NASDAQ: BTAI initiated the Phase 2 PLACIDITY trial evaluating BXCL501 to treat delirium-related agitation. The 20 subject-trial is designed to evaluate the safety, efficacy, and pharmacokinetics of BXCL501 in intensive care unit adult patients experiencing delirium-related agitation, including COVID-19 patients. 